跳至主要内容
临床试验/NCT00098358
NCT00098358Unknown2 期

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Proof of Concept Study of Zileuton IR in Patients With Moderate to Severe Facial Acne Vulgaris

Critical Therapeutics24 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2004年11月最近更新:
适应症
相关药物

试验速览

阶段
2 期
入组人数
90
试验地点
24
主要终点
Change in number of inflammatory lesions

研究概览

简要总结

Tissue inflammation is a major component of the acne disease process. Leukotriene B4 (LTB4) is thought to be a major player in the development of tissue inflammation. Synthesis of LTB4 is controlled by the enzyme 5-lipoxygenase. Zileuton blocks the activity of 5-lipoxygenase. This study will test the safety and efficacy of zileuton in the treatment of facial acne.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
12 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Moderate to severe facial acne vulgaris
  • 20 to 60 facial inflammatory lesions
  • 10 to 200 facial non-inflammatory lesions
  • No more than 3 facial nodular cystic lesions

排除标准

  • Uncontrolled systemic disease
  • Use of systemic or topical acne therapy within 14 days of study
  • Use of systemic retinoids within past 2 years
  • Skin diseases that interfere with acne counts
  • Active liver disease
  • Screening elevations in liver function tests
  • Positive serology for hepatitis B or C
  • Use of theophylline, warfarin, or propranolol within 7 days of study
  • Use of Singulair or Accolate within 14 days of study
  • Female patients who are pregnant or nursing

结局指标

主要结局

Change in number of inflammatory lesions

次要结局

  • Physician's global assessment scale
  • Change in number of non-inflammatory lesions
  • Change in total numbers of lesions
  • Change in sebum production

研究者

申办方类型
Industry

研究点 (24)

Loading locations...

相似试验